We study signal transduction pathways that are altered in a number of human diseases, including lung and upper-airway cancers and neurodegeneration. Clinically, our research is most developed in head and neck squamous cell carcinoma (HNSCC). We have developed new clinical proteomic technologies to quantify the proteome in archived FFPE tumor blocks.
Coupling these data with therapy and patient outcomes is revealing novel biomarkers. We have also opened our first clinical trial which is testing a the pyrimethamine drug as an inhibitor of the NRF2 pathway in HNSCC. Multiple clinical research projects and training opportunities are available for our students and postdocs.